Anti-Nicotinic Acetylcholine Receptor alpha 1 antibody [61] (ab24631)


  • Product nameAnti-Nicotinic Acetylcholine Receptor alpha 1 antibody [61]
    See all Nicotinic Acetylcholine Receptor alpha 1 primary antibodies
  • Description
    Rat monoclonal [61] to Nicotinic Acetylcholine Receptor alpha 1
  • Specificityab24631 reacts with Neuronal Nicotinic Acetylcholine Receptor a1-Subunits.
  • Tested applicationsSuitable for: ICC/IF, IPmore details
  • Species reactivity
    Reacts with: Mouse, Human, Torpedo
  • Immunogen

    Denatured Electophorus electricus acetylcholine receptors (AChRs).

  • EpitopeThis antibody binds to the cytoplasmic surface of native and denatured muscle AChR a1 subunits, within amino acids 371-386.
  • General notes

    ab24631 is useful in studying AChR synthesis and assembly.


  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: None
    Constituents: Ascites
  • Concentration information loading...
  • PurityAscites
  • Primary antibody notesab24631 is useful in studying AChR synthesis and assembly.
  • ClonalityMonoclonal
  • Clone number61
  • IsotypeIgG2a
  • Research areas


Our Abpromise guarantee covers the use of ab24631 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use at an assay dependent dilution.
IP 1/100.


  • FunctionAfter binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
  • Tissue specificityIsoform 1 is only expressed in skeletal muscle. Isoform 2 is constitutively expressed in skeletal muscle, brain, heart, kidney, liver, lung and thymus.
  • Involvement in diseaseDefects in CHRNA1 are a cause of multiple pterygium syndrome lethal type (MUPSL) [MIM:253290]. Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent.
    Note=The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs.
    Defects in CHRNA1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS) [MIM:601462]. SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes.
    Defects in CHRNA1 are a cause of congenital myasthenic syndrome fast-channel type (FCCMS) [MIM:608930]. FCCMS is a congenital myasthenic syndrome characterized by kinetic abnormalities of the AChR. In most cases, FCCMS is due to mutations that decrease activity of the AChR by slowing the rate of opening of the receptor channel, speeding the rate of closure of the channel, or decreasing the number of openings of the channel during ACh occupancy. The result is failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential.
  • Sequence similaritiesBelongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha-1/CHRNA1 sub-subfamily.
  • Cellular localizationCell junction > synapse > postsynaptic cell membrane. Cell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Acetylcholine receptor subunit alpha antibody
    • ACHA_HUMAN antibody
    • AChR antibody
    • ACHRA antibody
    • CHNRA antibody
    • Cholinergic receptor nicotinic alpha polypeptide 1 antibody
    • Cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) antibody
    • Chrna1 antibody
    • Nicotinic cholinergic receptor alpha 1 antibody
    • Schizophrenia neurophysiologic defect candidate antibody
    see all

References for Anti-Nicotinic Acetylcholine Receptor alpha 1 antibody [61] (ab24631)

This product has been referenced in:
  • Tzartos SJ  et al. Mapping of surface structures of electrophorus acetylcholine receptor using monoclonal antibodies. J Biol Chem 256:8635-45 (1981). Read more (PubMed: 6167581) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab24631.
Please use the links above to contact us or submit feedback about this product.